Thank you for visiting Gilead.com. Please explore this section for the latest news about Gilead, our groundbreaking research and our therapeutics.

Please see Gilead-at-a-Glance to learn more about the company and our portfolio of products.

Sign-up to receive email alerts whenever new company information is posted to the site.

Recent News

June 26, 2009
European CHMP Adopts Positive Opinion for Aztreonam Lysine

June 18, 2009
Gilead Sciences to Present at the Piper Jaffray 4th Annual Europe Conference on Wednesday, June 24

June 2, 2009
Gilead Sciences to Present at Two Upcoming Investor Conferences

May 28, 2009
Gilead Sciences' Marketing Authorisation Application for Regadenoson Validated by European Medicines Agency

May 22, 2009
Gilead Sciences Announces Changes to Cardiovascular R & D Organization Leadership

May 18, 2009
New Data for Gilead Sciences' Ambrisentan Show Clinical Improvements in a Diverse Pulmonary Hypertension (PH) Population

May 15, 2009
Gilead Sciences to Present at the Deutsche Bank 34th Annual Healthcare Conference on Tuesday, May 19

May 14, 2009
Gilead Sciences Files Second Patent Infringement Lawsuit Against Teva Pharmaceuticals

May 12, 2009
Gilead Palo Alto, Inc. Announces Tender Offer for Convertible Notes

May 8, 2009
Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients

April 21, 2009
Gilead Sciences Announces Record First Quarter 2009 Financial Results

April 17, 2009
Gilead Sciences Completes Acquisition of CV Therapeutics

April 17, 2009
Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV

April 15, 2009
Gilead Sciences Successfully Completes Tender Offer for Shares of CV Therapeutics With Over 88 Percent of Shares Tendered

April 14, 2009
Gilead Sciences to Release First Quarter 2009 Financial Results on Tuesday, April 21, 2009

April 13, 2009
Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009

April 6, 2009
Gilead Sciences Announces Notification of ANDA Filing for
Atripla(R)

April 2, 2009
Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints